CONCORD DRUGS
Back to Income Statement
|
CONCORD DRUGS Last 5 Year Revenue History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|
| Net Sales | ₹45 Cr | ₹45 Cr | ₹52 Cr | ₹59 Cr |
What is the latest Revenue of CONCORD DRUGS ?
| Year | Revenue |
|---|---|
| Mar2025 | ₹45 Cr |
| Mar2024 | ₹45 Cr |
| Mar2023 | ₹52 Cr |
| Mar2022 | ₹59 Cr |
How is Revenue of CONCORD DRUGS Trending?
| Years | Revenue | % Change | |
|---|---|---|---|
| Mar2025 | ₹45 Cr | 0.71 | |
| Mar2024 | ₹45 Cr | -13.74 | |
| Mar2023 | ₹52 Cr | -11.66 | |
| Mar2022 | ₹59 Cr | - | |
Compare Revenue of peers of CONCORD DRUGS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CONCORD DRUGS | ₹92.1 Cr | -2.6% | 4.5% | -17% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹449,228.0 Cr | 1.2% | 9.1% | 6.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹296,741.0 Cr | -2.7% | 22.2% | 70% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹176,413.0 Cr | -1% | 2% | 20.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹116,771.0 Cr | 1.5% | 13% | 12.1% | Stock Analytics | |
| CIPLA | ₹114,397.0 Cr | 1.7% | 7.8% | -7.3% | Stock Analytics | |
CONCORD DRUGS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CONCORD DRUGS | -2.6% |
4.5% |
-17% |
| SENSEX | 1.4% |
12.4% |
-1.7% |
You may also like the below Video Courses